Health-related quality of life, treatment satisfaction, adherence and persistence in &#946;-thalassemia and myelodysplastic syndrome patients with iron Overload receiving deferasirox : results from the EPIC clinical trial by J. Porter et al.
Hindawi Publishing Corporation
Anemia
Volume 2012, Article ID 297641, 10 pages
doi:10.1155/2012/297641
Research Article
Health-Related Quality of Life, Treatment Satisfaction,
Adherence and Persistence in β-Thalassemia and Myelodysplastic
Syndrome Patients with Iron Overload Receiving Deferasirox:
Results from the EPIC Clinical Trial
John Porter,1 Donald K. Bowden,2 Marina Economou,3 Jacques Troncy,4 Arnold Ganser,5
Dany Habr,6 Nicolas Martin,7 Adam Gater,8 Diana Rofail,8 Linda Abetz-Webb,8
Helen Lau,6 and Maria Domenica Cappellini9
1Department of Haematology, UCL Cancer Institute, University College London, Paul O’Gorman Building, 72 Huntley Street,
London WC1E 6BT, UK
2Monash Medical Centre, Melbourne, VIC 3168, Australia
3Thalassemia Clinical Care Services Unit, Hippokration General Hospital Thessaloniki, Egnatia Street 106, 54622 Thessaloniki, Greece
4Hematology, Hopital Edouard Herriot, 6 Rue Antoine Lumiere, 69008 Lyon, France
5Medizinische Hochschule Hannover (MHH), Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation,
Carl-Neuberg Strasse 1, 30625 Hannover, Germany
6Novartis Pharmaceutical Corporation, 180 Park Avenue, 105-3E065, Florham Park, NJ 07932-1080, USA
7Novartis Pharma AG Postfach, 4002 Basel, Switzerland
8Adelphi Values, Adelphi Mill, Grimshaw Lane, Bollington, Cheshire SK10 5JB, UK
9Universita di Milano, Can Granda Foundation IRCCS, Via F. Sforza 35, 20122 Milan, Italy
Correspondence should be addressed to John Porter, j.porter@ucl.ac.uk
Received 20 January 2012; Revised 1 May 2012; Accepted 19 May 2012
Academic Editor: Sezaneh Haghpanah
Copyright © 2012 John Porter et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Treatment of iron overload using deferoxamine (DFO) is associated with significant deficits in patients’ health-related quality of
life (HRQOL) and low treatment satisfaction. The current article presents patient-reported HRQOL, satisfaction, adherence, and
persistence data from β-thalassemia (n = 274) and myelodysplastic syndrome (MDS) patients (n = 168) patients participating
in the Evaluation of Patients’ Iron Chelation with Exjade (EPIC) study (NCT00171821); a large-scale 1-year, phase IIIb study
investigating the eﬃcacy and safety of the once-daily oral iron chelator, deferasirox. HRQOL and satisfaction, adherence, and
persistence to iron chelation therapy (ICT) data were collected at baseline and end of study using the Medical Outcomes Short-
Form 36-item Health Survey (SF-36v2) and the Satisfaction with ICT Questionnaire (SICT). Compared to age-matched norms,
β-thalassemia and MDS patients reported lower SF-36 domain scores at baseline. Low levels of treatment satisfaction, adherence,
and persistence were also observed. HRQOL improved following treatment with deferasirox, particularly among β-thalassemia
patients. Furthermore, patients reported high levels of satisfaction with deferasirox at end of study and greater ICT adherence,
and persistence. Findings suggest deferasirox improves HRQOL, treatment satisfaction, adherence, and persistence with ICT in
β-thalassemia and MDS patients. Improving such outcomes is an important long-term goal for patients with iron overload.
1. Introduction
Regular blood transfusions are essential for the manage-
ment of haematological conditions such as β-thalassemia
major and myelodysplastic syndromes (MDS). As a result,
however, patients with these conditions are susceptible to
the development of transfusion-dependent iron overload
(hemosiderosis or secondary iron overload). In the absence
of a naturally occurring physiological mechanism for the
removal of excess iron in the body, life-long treatment and
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adherence to iron chelation therapy (ICT) are necessary to
prevent the morbidity and mortality that may result if excess
iron is allowed to accumulate [1, 2].
Deferoxamine (DFO), most commonly delivered by con-
tinuous subcutaneous infusion over 8 to 12 hours a day,
is the oldest available form of ICT used by patients with
transfusion-dependent disorders. Prior research, albeit in
small sample sizes, has indicated significant deficits in health-
related quality of life (HRQOL) among patients receiving
DFO for the treatment of transfusion-dependent iron over-
load, compared to values from age-matched normative pop-
ulations [3, 4]. In particular, the time-consuming nature of
DFO regimens and side eﬀects associated with this form
of ICT (including local site reactions) [5–7] can have a
detrimental impact on numerous facets of patients’ lives,
including work; social activities; sex life; sleep; emotional
well-being [8]. As a result, patient satisfaction with DFO
treatment regimens is low and suboptimal adherence is
common among patients [3, 4]. Improvements in ICT
administration convenience and tolerability are expected to
improve patient’s satisfaction with ICT and HRQOL, thus
promoting adherence to ICT regimens and potentially reduc-
ing iron overload-relatedmorbidity/mortality and associated
healthcare costs [1, 9, 10].
Deferasirox (Exjade) is an oral ICT first approved in
2005 and is the most widely prescribed ICT today [11].
Deferasirox has been shown to be an eﬃcacious and generally
well-tolerated therapy for the treatment of iron overload in
β-thalassemia and MDS patients [12, 13]. Findings from
randomised control trials comparing outcomes in patients
with iron overload treated using either deferasirox or DFO
have also suggested the superiority of deferasirox in terms
of treatment satisfaction and adherence [14, 15]. How-
ever, additional research using validated patient-reported
outcome (PRO) measures is needed in order to better
understand the added benefits of deferasirox over DFO in
terms of reducing HRQOL burden and improving treatment
satisfaction, adherence, and persistence among patients with
transfusion-dependent iron overload. The current work
seeks to address these needs by presenting and discussing
PRO findings from the Evaluation of Patients’ Iron Chelation
with Exjade (EPIC) study (NCT00171821), a large-scale
prospective study designed to investigate the eﬃcacy and
safety of deferasirox in patients diagnosed with transfusion-
dependent iron overload [12, 13].
2. Methods
2.1. Study Design. The EPIC study was a prospective, 1-year,
multicentre, open-label phase IIIb trial conducted by 136
investigators across 23 countries [12, 13]. A PRO sub-
study within the EPIC trial was conducted to assess self-
reported HRQOL and treatment satisfaction, adherence,
and persistence in patients with transfusion-dependent iron
overload. Based on the availability of validated questionnaire
translations, the PRO substudy included participating study
sites in Australia, Belgium, France, Germany, Greece, Italy,
the Netherlands, and the UK. Study findings reported here
focus specifically on data from adult patients (≥16 years of
age) with β-thalassemia and MDS. Based on the inherent
diﬀerences in the underlying disease and patient profiles,
study findings for patients with β-thalassemia and MDS will
be reported separately. Of note, however, PRO data were also
collected from patients with a variety of other transfusion-
dependent disorders (including sickle cell disease, aplastic
anemia, and other rare anemias) but sample sizes were
considered too small (n < 30) for evaluable analysis as sep-
arate subgroups.
In accordance with EPIC trial selection criteria, all pa-
tients enrolled in this study were required to have trans-
fusion-related iron overload, evident by a serum ferritin level
of ≥1000 ng/mL or with LIC > 2mg Fe/g dw, as determined
by R2-Magnetic Resonance Imaging (MRI) [12, 13]. Patients
unsuitable for participation in a clinical study from a clinical
perspective (e.g., presence of systemic diseases which would
prevent the patient from undergoing treatment) or a practi-
cal perspective (e.g., history of non-compliance to medical
regimens) were excluded from the study. Assessments of
HRQOL and satisfaction, adherence, and persistence to ICT
were collected at baseline and at the end of the study (EOS;
week 52 or at time of early study discontinuation), where
appropriate, using the Medical Outcomes Short-Form 36-
item Health Survey (SF-36v2) and the Satisfaction with
ICT Questionnaire (SICT). Questionnaires were provided
to patients in the native language of the respective country
in which the patient was enrolled. Both questionnaires
have been linguistically validated for use in the respective
countries, ensuring the cross-cultural equivalence of the
questionnaires and enabling data collected from diﬀerent
countries to be considered in a single-pooled dataset.
2.2. Ethics. The EPIC study was conducted in accordance
with the Declaration of Helsinki; the International Confer-
ence on Harmonization (ICH) Tripartite Guidelines for
Good Clinical Practice 1996; the Rules Governing Medic-
inal Products in the European Community (Directive
91/507/EEC); the US 21 Code of Federal Regulations dealing
with clinical studies. Written informed consent was obtained
from all patients prior to participation in the PRO substudy.
2.3. PRO Measures
2.3.1. The Medical Outcomes Short-Form 36-Item Health Sur-
vey (SF-36v2). The SF-36v2 is a self-administered question-
naire comprising 36-items measuring eight dimensions of
general HRQOL: physical functioning (10 items), role limi-
tation due to physical health problems (4 items), bodily pain
(2 items), general health perceptions (5 items), vitality (4
items), social functioning (2 items), role limitations due to
emotional problems (3 items), and general mental health (5
items). In addition to scores for individual dimensions, two
summary scores assessing physical and mental dimensions of
health and well-being can also be calculated: Physical Com-
ponent Summary (PCS) score and the Mental Component
Summary (MCS) score, respectively.
Although specific “tools” for the assessment of HRQOL
have been developed for thalassemia [16], the SF-36 has the
advantage of having been used extensively within clinical
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trials and academic studies, across a wide range of disease
areas, including β-thalassemia and MDS [3, 17–20]. The
psychometric validity and reliability of the instrument as
a generic measure of health-related functional status and
well-being is well established [21–23]. In this study, the SF-
36v2 was collected from patients at both baseline and EOS.
All data were handled and scored in accordance with the
developer’s instructions: item scores for each dimension were
coded, summed, and transformed to a scale from 0 (worst
possible health state) to 100 (best possible health state),
whereby higher values indicate better HRQOL. Domain
scores were only calculated if at least half of all items
comprising a domain were completed by the patient; missing
data was not imputed [22].
2.3.2. Satisfaction with ICT Questionnaire (SICT). The SICT
is a questionnaire designed specifically to assess patient
satisfaction with ICT regimens [24]. It comprises 19 items
assessing four domains of patient satisfaction: perceived
eﬀectiveness of ICT (PE), burden of ICT (BD), acceptance
of ICT (AC), and side eﬀects of ICT (SE). Patients rate all
items on a response scale from 1 “very dissatisfied” to 5
“very satisfied”. Domain scores are calculated as the mean
score across constituent items and a higher score indicates
greater satisfaction with respect to the questionnaire domain.
As with the SF-36v2, domain scores were calculated if at least
half of all items comprising a domain were completed by the
patient; no missing data was imputed [24].
In addition, the SICT also includes three individual items
designed to assess adherence to ICT “How often did you fol-
low the chelation therapy regimen exactly as recommended
by your doctor?”, ICT persistence “How often did you think
about stopping your chelation therapy?”, and diﬃculties
remembering to take ICT “How often did you have trouble
remembering to take your chelation therapy?”. All three items
are assessed on a 5-point Likert scale from 1 “Always” to
5 “Never” and are designed to be interpreted as standalone
items of the respective concepts.
Previous studies in patients with a variety of transfusion-
dependent haematological disorders have provided evidence
that the SICT is a reliable and valid measure of iron overload
patients’ satisfaction, adherence, and persistence to ICT
regimens [24, 25]. All patients participating in the PRO
substudy completed the SICT at EOS. Only patients with
prior history of ICT were required to complete the SICT at
baseline; the SICTwas not relevant at this timepoint for those
patients with no prior history of ICT.
2.3.3. Statistical Analyses and Data Interpretation. Descrip-
tive statistics for subscale domains and summary component
scores of the SF-36v2 were computed at baseline and EOS. To
highlight the HRQOL burden associated with iron overload,
mean SF-36 domain, and summary scores at baseline, and
EOS were compared to published data of patients with β-
thalassemia or MDS and age-matched norms derived from
the UK general population [3, 17, 22, 26]. Confidence
interval estimates were used to evaluate the significance of
diﬀerences in observed study means relative to other refer-
ence groups. SICT domain scores and responses to questions
regarding patient-reported adherence and persistence with
ICT therapy utilization were also summarized at baseline and
EOS.
Relevant diﬀerences in group means between study and
other reference populations for SF-36 domain scores (e.g.,
disease-specific and UK general population) were evaluated
using a distribution-based approach for establishing clini-
cally meaningful diﬀerence. In this regard, diﬀerences that
are 0.5 standard deviation (SD) units of a baseline score were
characterized as clinically meaningful [27–29].
Analysis of questionnaires at baseline and EOS (e.g., week
52 or at time of early study discontinuation) was undertaken
only in cases where sample sizes were large enough (n >
30) for statistical analyses. Data were presented separately
for patients with underlying β-thalassemia and MDS due
to inherent diﬀerences in disease populations and patient
profiles.
3. Results
3.1. Demographic and Clinical Characteristics. The demo-
graphic and clinical characteristics of β-thalassemia (n =
274) and MDS (n = 168) patients evaluated in this PRO sub-
study are displayed in Table 1 and are generally similar to
those of the overall β-thalassemia and MDS populations
enrolled in the EPIC trial [12, 13]. As expected, the mean
age of patients with MDS was considerably higher than
the mean age of patients with β-thalassemia. Almost all β-
thalassemia patients (n = 270; 98.5%) had a history of prior
ICT, with 66.4% (n = 184) having previously received DFO
monotherapy and 30.3% (n = 84) having previously received
DFO and deferiprone. Only 51.8% (n = 87) of MDS patients
had a history of prior ICT, however, with 37.5% (n = 63)
of the MDS sample having previously received DFO mono-
therapy and 8.3% (n = 14) having previously received DFO
and deferiprone. As such, where relevant, diﬀerences be-
tween MDS patients with a history of ICT and ICT-naı¨ve
patients are highlighted. Note, however, that sample sizes of
evaluable data do not allow for statistical comparison of dif-
ferences between these two groups.
3.2. Changes in HRQOL following Treatment with Deferasirox
3.2.1. β-Thalassemia Patients. At baseline, mean scores for 6
of the 8 SF-36 domains among patients with β-thalassemia
were notably lower than equivalent scores derived from UK
norms for persons aged 25 to 34 years (the exceptions being
vitality and mental health). Of these domains, diﬀerences
in scores for physical functioning, role-physical, and gen-
eral health at baseline among patients with β-thalassemia,
compared to UK general population norms, were at a level
considered to be clinically meaningful; indicating significant
burden within this population. However, baseline SF-36
domain scores among these patients were similar to historical
reference patients previously receiving infused chelation
therapy as reported by Payne et al. and in which 82% of
patients were β-thalassemia patients [3] (Figure 1).
Mean SF-36 PCS and MCS scores for β-thalassemia
patients at baseline (x = 45.64 [SD = 9.25] and x = 47.72
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Table 1: Demographic and clinical characteristics of β-thalassemia and MDS patients.
β-thalassemia (N = 274) MDS (N = 168)
Mean age (SD) 26 (11.5) 68 (10.3)
Males, n (%) 127 (46.4) 96 (57.1)
Age groups, n (%)
<6 yrs 17 (6.2) 0 (0)
6 to <12 yrs 25 (9.1) 0 (0)
12 to <16 yrs 15 (5.5) 0 (0)
16 to <50 yrs 213 (77.7) 4 (2.4)
50 to <65 yrs 4 (1.5) 55 (32.7)
≥65 yrs 0 (0) 109 (64.9)
Prior chelation therapy, n (%)
No 4 (1.5) 81 (48.2)
Yes 270 (98.5) 87 (51.8)
Prior chelation therapy, n (%)
None 4 (1.5) 81 (48.2)
DFO only 184 (66.4) 63 (37.5)
Deferiprone only 2 (0.7) 9 (5.4)
DFO and deferiprone∗ 84 (30.3) 14 (8.3)
Other ICT 3 (1.1) 1 (0.6)
∗
Patients may have received both DFO and deferiprone as prior chelation therapies, but these may not have been in combination.
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Figure 1: Mean SF-36 domain scores for β-thalassemia population versus disease-related and general population references at baseline and
EOS. Data illustrated in the above figure are representative of the mean and 95% confidence interval estimates of the mean as calculated
using the formula: 1.96 ∗ standard deviation ÷√n. Reference data for ICT patients were based on Payne et al. [3] (where 82% of patients in
this study were thalassemia patients); UK norms from Jenkinson et al. [42] and direct email communications from Dr. Jenkinson on Oct 24,
2011 with age-specific norms.
[SD = 10.63], resp.) were also lower compared to UK norms
(by −6.94 and −0.35 points, resp.); however, only the PCS
score was substantially diﬀerent and considered clinically
meaningful. Relative to other patients with a history of
receiving infusional ICT, mean summary component scores
at baseline for patients with β-thalassemia in the EPIC study
were similar.
Mean SF-36 domain scores at EOS were generally
higher following treatment with deferasirox and closer to
population norm scores for the UK general population and
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Figure 2: Mean SF-36 domain scores for MDS population versus MDS and general population references at baseline and EOS. Data
illustrated in the above figure are representative of the mean and 95% confidence interval estimates of the mean as calculated using the
formula: 1.96∗ standard deviation ÷√n. Transfusion-dependent MDS patient reference data reported by Jansen et al. [17]; UK norms from
Jenkinson et al. [42] and direct email communications from Dr. Jenkinson on Oct 24, 2011 with age-specific norms.
patients previously receiving infusional chelation therapy
[3]. Meaningful changes in scores from baseline to EOS were
observed for bodily pain, role-physical, and role-emotional
in patients with β-thalassemia. Mean SF-36 domain scores
at EOS were lower compared to UK population norms
for physical functioning, role-physical and general health
domains, but only the general health domain score at EOS
was lower than population norms to a clinically meaningful
degree. Mean SF-36 PCS and MCS scores were also higher
at EOS compared to baseline (x = 48.15 [SD = 9.03] and
x = 48.67 [SD = 9.52], resp.). PCS scores were, however,
still substantially lower than population norms such that the
diﬀerence can be considered clinically meaningful.
3.2.2. MDS Patients. In patients with MDS, mean baseline
scores for all SF-36 domains were lower than age-matched
UK norms for persons aged 65–74 years but were similar to
other patients with MDS (Figure 2) as previously reported
by Jansen et al. [17]. Diﬀerences between MDS and the
UK normative sample were also at the level considered
to be clinically meaningful for physical functioning, role-
physical, general health, vitality, social functioning, and role-
emotional domains. Mean SF-36 PCS and MCS scores for
MDS patients at baseline (x = 35.47 [SD = 8.58] and
x = 47.16 [SD = 11.29], resp.) were also lower than those
derived from the UK normative sample (−9.00 and −5.12,
resp.), however, only diﬀerences in PCS were of a clinically
meaningful magnitude. Relative to other MDS patients as
reported by Jansen et al. (2003), mean summary component
scores at baseline for patients with MDS in the EPIC study
were similar [17].
In patients with MDS, mean SF-36 domain scores were
lower at EOS compared to age-matched UK population
norms for all SF-36 domain scores. Mean scores at EOS were
no diﬀerent from means of MDS patients as reported by
Jansen et al. [17]. Except for the bodily pain domain, all
other functional and well-being domains of the SF-36 scale
were lower than UK norms to a clinically meaningful degree.
Compared to baseline, PCS scores remained relatively stable
(x = 35.71 [SD = 9.64]), but MCS scores declined at EOS
(x = 43.56 [SD = 11.79]). At EOS, deficits for both PCS
and MCS were lower than UK norms to a substantial and
clinically meaningful degree.
Further analysis of SF-36 scores for MDS patients with
and without prior ICT history suggest that ICT-naı¨ve pa-
tients had at baseline lower PCS scores and lower domain
scores for physical functioning, role-physical, bodily pain,
and general health domains, compared to patients with prior
experience of ICT. However, ICT naı¨ve patients had higher
MCS scores and scores for all constituent domains, except for
vitality (Table 2). Scores for all SF-36 domains and summary
components were lower at EOS compared to baseline among
patients with prior history of ICT. SF-36 domains for ICT-
naı¨ve patients were higher for physical functioning, role-
physical, general health, vitality, and PCS but were lower for
other domains and MCS at EOS.
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Table 2: Mean (SD) SF-36 domain and summary scores among MDS patients according to prior ICT history.
Baseline mean (SD) EOS mean (SD)Reference MDS
population
(n = 50): mean (SD)
Age-matched UK
norms: mean (SD) Prior ICT
(N = 59–62)
ICT Naı¨ve
(N = 34-35)
Prior ICT
(N = 38–40)
ICT Naı¨ve
(N = 32–35)
Physical functioning
48.1 77.42 53.60 44.56 47.43 48.79
(30.6) (25.38) (21.35) (17.94) (24.39) (23.29)
Role-physical
39.2 78.16 36.39 26.43 30.21 29.66
(42.5) (28.11) (39.21) (36.85) (40.90) (35.60)
Bodily pain
66.6 71.52 65.61 64.69 63.23 59.77
(31.2) (26.46) (27.43) (27.16) (28.53) (31.85)
General health
41.5 66.24 42.70 40.72 37.78 41.55
(21.3) (22.57) (18.94) (20.00) (20.01) (15.92)
Vitality
50.6 57.79 43.25 37.35 42.89 40.20
(25.3) (21.28) (19.02) (15.92) (24.10) (16.81)
Social functioning
67.0 81.08 68.55 71.07 62.18 63.21
(29.6) (26.14) (29.75) (23.24) (25.57) (21.21)
Role-emotional
59.0 84.11 57.18 61.90 41.23 51.96
(41.4) (24.41) (44.05) (41.34) (43.45) (45.83)
Mental health
72.3 73.84 66.78 69.06 60.07 64.47
(20.9) (19.35) (22.34) (18.54) (22.85) (23.01)
Physical component
summary
35.7 44.47 36.97 33.10 36.21 35.11
(11.7) (12.32) (8.48) (8.31) (8.70) (10.80)
Mental component
summary
48.9 52.28 46.32 48.49 42.14 45.27
(12.6) (9.89) (12.02) (10.04) (11.61) (11.97)
Transfusion-dependent MDS patient reference data reported by Jansen et al. [17]; UK norms from Jenkinson et al. [42] and direct email communications
from Dr. Jenkinson on Oct 24, 2011 with age-specific norms.
3.3. Changes in ICT Satisfaction following Treatment
with Deferasirox
3.3.1. β-Thalassemia Patients. At baseline, patients with β-
thalassemia and prior history of ICT were generally satisfied
with the perceived eﬀectiveness of their ICT prior to
initiation of deferasirox in the EPIC study but were neither
satisfied nor dissatisfied with side eﬀects of ICT, acceptance
of ICT and burden of ICT as measured by SICT domains
(Figure 3). Compared to baseline, patient-reported satisfac-
tion associated with side eﬀects of ICT, acceptance of ICT,
and burden of ICT SICT domains increased with deferasirox
by ≥1.4 points at EOS.
3.3.2. MDS Patients. At baseline, patient-reported satisfac-
tion with ICT was high (>3.5) among MDS patients with
prior history of ICT as measured by SICT domains of per-
ceived eﬀectiveness of ICT, side eﬀects of ICT, and burden of
ICT (Figure 4). Patients were neither satisfied or dissatisfied
on SICT domain of acceptance of ICT at baseline. Compared
to baseline, patient-reported satisfaction with ICT-related
side eﬀects, acceptance, and burden were higher at EOS
following treatment with deferasirox based on SICT domain
scores. Scores for the perceived eﬀectiveness of ICT SICT
domain remained stable between baseline and EOS.
SICT data were also evaluated at EOS for those MDS
patients with no prior history of ICT. Notably, the SICT
domain scores reported were comparable to EOS scores for
patients with prior ICT for SICT domains: side eﬀects of ICT
(x = 4.18, SD = 0.17), acceptance of ICT (x = 4.17, SD =
0.69), and burden of ICT (x = 4.51, SD = 0.55). Patient-
reported satisfaction for the perceived eﬀectiveness of ICT
domain was also high at EOS (x = 4.25, SD = 0.60).
3.4. Changes in ICT Adherence following Treatment with
Deferasirox. Following treatment with deferasirox, the pro-
portion of β-thalassemia patients who reported always
following their ICT regimen as recommended by their doctor
increased from 32.4% (n = 58/179) at baseline to 67.1% (n =
116/173) at EOS. Patient-reported adherence was also high
among patients with MDS who had a prior history of ICT
at baseline where 62.5% (n = 35/56) of patients reported
having always followed their ICT regimen as they were
told by their doctor. Following treatment with deferasirox,
patient’s self-reported adherence to ICT increased to 85.7%
(n = 36/42) at EOS. Similarly, patient-reported adherence
among MDS patients with no prior history of ICT at EOS
was high, with 82.9% (n = 29/35) of patients reporting that
they always followed their ICT regimen as they were told by
their doctor.
3.5. Changes in ICT Persistence following Treatment with De-
ferasirox. Following treatment with deferasirox in the EPIC
study, the proportion of patients with β-thalassemia who
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Figure 4: Mean SICT domain scores at baseline and EOS for MDS
population with prior history of ICT.
never thought about stopping ICT increased from 40.8%
(n = 73/179) at baseline to 76.3% (n = 132/173) at EOS.
Among patients with MDS and a prior history of ICT, the
proportion of patients who never thought about stopping
ICT was high at baseline (75.9%, n = 41/54), but decreased
slightly at EOS following treatment with deferasirox (69.0%,
n = 29/42). Persistence to ICT, however, was high at EOS
among MDS patients with no prior history of ICT; 77.1%
(n = 27/35) of this population never thought about stopping
ICT at EOS.
4. Discussion
The EPIC study is the largest prospective evaluation of any
iron chelation therapy conducted to date. Findings from this
study have demonstrated that deferasirox is an eﬃcacious
and generally well-tolerated treatment for the treatment of
iron overload in patients with transfusion-dependent disor-
ders such as β-thalassemia and MDS [12, 13]. In addition,
this study provided a unique opportunity to collect data con-
cerning the role that deferasirox can play in addressing
HRQOL concerns associated with iron chelation therapies
and how deferasirox may help address issues related to treat-
ment satisfaction, adherence, and persistence among patients
with iron overload.
SF-36 data collected for β-thalassemia patients at baseline
suggest that these patients have lower HRQOL compared
to age-matched norms on almost all facets of HRQOL
assessed within the SF-36. The greatest deficits were seen
in related “physical” domains of the SF-36 (e.g., physical
functioning, role-physical, bodily pain, and general health).
These findings are supportive of prior investigations among
smaller samples of β-thalassemia patients and confirm asser-
tions that β-thalassemia is a debilitating disease [3, 4, 18].
Similarly, as reflective of prior research, deficits on all facets
of HRQOL were also observed among patients with MDS
[17, 30]. Notably, however, HRQOL deficits appeared greater
among patients with MDS compared to those with β-
thalassemia.
The burdensome nature of infused ICT (DFO) has been
cited as a contributory factor to diminished HRQOL do-
mains observed in patients with transfusion-dependent dis-
orders [3, 4, 8]. As such there is an expectation that, com-
pared to DFO, oral ICT such as deferasirox will have a less
detrimental eﬀect on patient’s HRQOL. Although the EPIC
study does not provide a direct head-to-head comparison
of deferasirox versus DFO, the prospective evaluation of
HRQOL over time following initiation of deferasirox pro-
vides unique insight into the diﬀerential impact of both
infused and oral ICT onHRQOL among patients with β-tha-
lassemia and MDS. This is especially true for β-thalassemia
patients, many of whom had been receiving DFO prior to
enrolment in the EPIC study. The prospective assessment
of HRQOL over time in MDS patients also addresses the
limitations of prior research in MDS patients which, in col-
lecting HRQOL data at one time point, give little indication
of changes in HRQOL in this population over time.
Observations from the EPIC study suggest that deferasir-
ox was associated with directional improvements in all facets
of HRQOL as assessed by the SF-36 among patients with β-
thalassemia which were similar to prior reported studies of
similar populations [3, 17]. Ofmost note were improvements
in bodily pain; a key but often overlooked symptom of β-
thalassemia [31]. In contrast to patients with β-thalassemia,
patients with MDS in the EPIC study had slightly lower
mean HRQOL domain scores at EOS, however, mean scores
were similar to observations reported by Jansen et al. [17]
and may be representative of declining prognosis and disease
progression with transfusion dependence and the need for
supportive care [32, 33].
Observed diﬀerences in HRQOL between the two popu-
lationsmust be interpreted in the context of the demographic
and clinical characteristics of the respective populations. In
contrast to the β-thalassemia which is a genetic condition
typically diagnosed in early years of life, MDS is an acquired
disorder with the majority of cases occurring in patients over
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the age of 60 [34]; a diﬀerence reflected in the substudy
samples for the EPIC trial (mean age of 26 versus 68 years,
resp.). In addition, modern-day therapy has increased life
expectancy for β-thalassemia patients, such that patients can
now live for decades [35, 36]. Past research has also indi-
cated that HRQOL in patients with β-thalassemia remains
relatively stable over time; adding confidence that changes
observed in this study are a result of the study treatment
(e.g., switch to deferasirox) as opposed to statistical artifact
[37]. By contrast, the prognosis of patients with MDS is
generally poor due to disease progression, deterioration, and
increasing transfusion dependence [38]. The presence of
comorbid conditions (e.g., diabetes, coronary heart disease,
or chronic pulmonary obstructive disease) which are increas-
ingly prevalent among elderly populations also complicate
the management of MDS and contribute to poor risk among
these patients [39]. As such, HRQOL may be expected to
deteriorate among MDS populations over time, independent
of the form of ICT that is received by the patient.
The EPIC study provides unique insight into the impact
that deferasirox may have on patients HRQOL over a one-
year period. However, the key to minimising long-term mor-
bidity and mortality in patients with transfusion-dependent
disorders is ensuring patient’s adherence to recommended
ICT regimens. The burdensome nature of infusional ICT
regimens or iterative ICT combination regimens may com-
plicate compliance and result in suboptimal adherence, and
persistence [3, 4]. This was also evident in the present
study, particularly among patients with β-thalassemia where
approximately 40% of patients at baseline self-reported that
they always followed their treatment regimen as recom-
mended by their doctor (e.g., adherence) and never thought
about stopping ICT treatment (e.g., persistence). However,
self-reported adherence and persistence among patients with
β-thalassemia increased at EOS following treatment with
deferasirox (67.1% and 76.3%, resp.). Likewise, the propor-
tion of MDS patients with prior history of ICT who reported
always following their ICT regimen as recommended by their
doctor increased at EOS compared to baseline. Self-reported
persistence with ICT was slightly lower at EOS compared to
baseline (75.9% and 69.0% never thought about stopping
their ICT at baseline and EOS, resp.) among MDS patients
with prior history of ICT which may be associated with
underlying disease progression.
Patients who are less satisfied with prescribed treatment
are expected to be less likely to adhere to recommended
treatment protocols. Consistent with this, patients with β-
thalassemia in the EPIC study demonstrated a higher level
of satisfaction with ICT at EOS following treatment with
deferasirox, particularly in relation to practical aspects of ICT
such as side-eﬀects, burden, and acceptability of treatment
regimen which coincided with higher self-reported adher-
ence and persistence with deferasirox at EOS. In MDS pa-
tients with prior history of ICT, notable improvements in
satisfaction with ICT were recorded between baseline and
EOS and higher self-reported adherence. This observation
suggests that the directional changes in HRQOL in patients
with MDS may be associated with other factors such as
progressive underlying disease, complications of older age,
among others, and the may not be related to study treatment.
Furthermore, levels of satisfaction among patients withMDS
and no prior history of ICT were also high at EOS, oﬀering
further support that the directional changes in aspects of
HRQOL between baseline and EOS may be attributable to
other factors.
In reflecting on potential limitations of the present study,
the number of MDS patients for whom there was evaluable
data should be considered. The high rate of study discontin-
uations amongMDS patients participating in the EPIC study
is acknowledged as source of potential bias in these data and
is a key factor limiting the availability of evaluable data in
this substudy. As detailed by Gattermann et al. (2010), of
341 patients with MDS enrolled, 175 patients completed the
study (median duration of treatment: 50.6 weeks) whereas
166 discontinued (rate: 48.7%) with the primary reason for
study discontinuation being due to adverse events (n =
78) [13]. Nonetheless, when interpreting findings from the
current study, it is necessary to consider that HRQOL,
treatment satisfaction, adherence, and persistence may be
negatively aﬀected in those patients discontinuing treatment
due to adverse events.
In interpreting the findings of this study, it is also impor-
tant to appreciate that the defining features of controlled
clinical studies (e.g., study selection criteria, predetermined
assessment schedules, study treatment)may introduce bias to
the evaluation of health outcomes (e.g., HRQOL, treatment
satisfaction, adherence, persistence, etc.). In particular, the
exclusion of participants with a history of poor compliance
to medical regimens may have aﬀected ratings of adherence,
and persistence at baseline and EOS. As such, further con-
sideration of naturalistic studies would help to establish the
real-world validity of observed changes in HRQOL, treat-
ment satisfaction, adherence and persistence associated with
deferasirox observed in the EPIC study. A recent retrospec-
tive assessment of iron chelation adherence from the Tha-
lassemia Clinical Research Network (TRCN) also documents
high patient-reported adherence with deferasirox [40, 41].
With this end in mind, the present study provides further
evidence of the validity of the SF-36 and SICT as measures of
HRQOL and treatment satisfaction/adherence/persistence,
respectively, and supports their use in future studies of
transfusion-dependent conditions and ICTs. Standardisation
of PRO assessments in future studies (using the SF-36 and
SICT, e.g.) is particularly important for enabling meaningful
comparisons to be made between varying ICT regimens.
5. Conclusions
This substudy represents the largest prospective evaluation of
patient-reported outcomes with deferasirox to date. Findings
indicate improvements in patient-reported HRQOL, ICT
satisfaction, adherence, and persistence following treatment
with deferasirox particularly among β-thalassemia patients,
the majority of whom had been using infused ICT prior to
enrolment in the study. Patient satisfaction with deferasirox
is high and patients receiving deferasirox report being more
likely to adhere and persist with ICT. Such evaluations are
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vital for improving both the long-term health outcomes
and survival of patients with transfusion-dependent iron
overload and minimising future health resource use.
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